Keith Katkin
Director at Emergent BioSolutions Inc. (EBS) since April 2022
Keith Katkin has filed 23 insider reports with the SEC since February 2021, as director at Emergent BioSolutions Inc. (EBS), director at Syndax Pharmaceuticals Inc (SNDX) and director at Eledon Pharmaceuticals, Inc. (ELDN). In the last 12 months Keith Katkin sold $128K of stock on the open market. In the latest filing, on May 4, 2026, Keith Katkin sold 15,481 shares of Emergent BioSolutions Inc. (EBS) for $128K at an average of $8.28.
- Filings
- 23
- Companies
- 3
- Bought on market
- $91.1K
- Sold on market
- $1.05M
Companies where Keith Katkin is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Directorsince April 2022 | 96,294 | $178K | $5.05 | May 4, 2026 | |||
| Director | 124,000 | $91.1K | $877K | $9.11 | $8.72-4.3% | Feb 6, 2026 | |
| Director | 8,575 | $1.78 | Jan 16, 2026 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.
Every filing
- Apr 30, 2026-$128KEBSDirector Katkin Keith was granted 25,344 shares and sold $128,183 worth of shares (15,481 units at $8.28) as part of a pre-agreed trading plan, increasing direct ownership by 11% to 96,294 units (withholding tax)Form 4Grant or awardOpen-market sale10b5-1 plan
- Apr 30, 2026~$128KEBSKeith Katkin plans to sell 15,481 shares (~$128K)Form 144Planned sale10b5-1 plan
- Feb 4, 2026SNDXDirector Katkin Keith was granted 24,000 shares, increasing direct ownership by 24% to 124,000 unitsForm 4Grant or award
- Jan 10, 2026ELDNDirector Katkin Keith converted options into 8,575 sharesForm 4Exercise or conversion of a derivative
- May 23, 2025-$49.4KEBSDirector Katkin Keith sold $49,417 worth of shares (7,844 units at $6.30), decreasing direct ownership by 8% to 86,431 unitsForm 4Open-market sale10b5-1 plan
- May 23, 2025~$49.4KEBSKeith Katkin plans to sell 7,844 shares (~$49.4K)Form 144Planned sale10b5-1 plan
- May 19, 2025+$91.1KSNDXDirector Katkin Keith bought $91,120 worth of shares (10,000 units at $9.11), increasing direct ownership by 11% to 100,000 unitsForm 4Open-market purchase
- Apr 30, 2025EBSDirector Katkin Keith was granted 34,403 shares, increasing direct ownership by 57% to 94,275 unitsForm 4Grant or award
- Feb 5, 2025SNDXDirector Katkin Keith was granted 25,000 shares, increasing direct ownership by 38% to 90,000 unitsForm 4Grant or award
- Jan 10, 2025ELDNSEC Form 4 filed by Director Katkin KeithForm 4Grant or award
- May 23, 2024EBSKatkin Keith was granted 17,430 shares, increasing direct ownership by 41% to 59,872 unitsForm 4Grant or award
- Feb 7, 2024SNDXKatkin Keith was granted 17,000 shares, increasing direct ownership by 35% to 65,000 unitsForm 4Grant or award
- May 25, 2023EBSSEC Form 4 filed by Katkin KeithForm 4Grant or award
- May 1, 2023ELDNSEC Form 4 filed by Katkin KeithForm 4Grant or award
- Feb 2, 2023SNDXSEC Form 4: Katkin Keith was granted 16,000 shares, increasing direct ownership by 50% to 48,000 unitsForm 4Grant or award
- Feb 1, 2023ELDNSEC Form 4 filed by Katkin KeithForm 4Grant or award
- Oct 6, 2022-$774KSNDXSEC Form 4: Katkin Keith exercised 29,899 shares at a strike of $8.20 and sold $774,411 worth of shares (29,899 units at $25.90) as part of a pre-agreed trading planForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Oct 4, 2022-$103KSNDXSEC Form 4: Katkin Keith exercised 4,101 shares at a strike of $8.11 and sold $102,777 worth of shares (4,101 units at $25.06) as part of a pre-agreed trading planForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Apr 2, 2022EBSSEC Form 4: Katkin Keith was granted 8,595 sharesForm 4Grant or award
- Apr 1, 2022EBSSEC Form 3: New insider Katkin Keith claimed no ownership of stock in the companyForm 3New insider
- Feb 2, 2022SNDXSEC Form 4: Katkin Keith was granted 16,000 shares, increasing direct ownership by 100% to 32,000 unitsForm 4Grant or award
- Feb 1, 2022ELDNSEC Form 4 filed by Katkin KeithForm 4Grant or award
- Feb 3, 2021SNDXSEC Form 4: Keith Katkin was granted 16,000 units of Common StockForm 4Grant or award
Compare Keith Katkin with
- Keith Katkin vs Aaron Ondrey1 shared
- Keith Katkin vs Paul Anthony Williams1 shared
- Keith Katkin vs David-Alexandre C Gros1 shared
- Keith Katkin vs Steven Perrin1 shared
- Keith Katkin vs Michael A Metzger1 shared
- Keith Katkin vs Nicholas A.J. Botwood1 shared
Other insiders at the same companies
- Aaron OndreySNDX
- Paul Anthony WilliamsEBS
- Stephanie DuatschekEBS
- David-Alexandre C GrosELDN
- Steven PerrinELDN
- Michael A MetzgerSNDX
- Nicholas A.J. BotwoodSNDX
- Richard S LindahlEBS
- Coleen GlessnerEBS
- William HartzelEBS
- Keith A. GoldanSNDX
- Sujata Tyagi DayalEBS
- Donald W DeGolyerEBS
- Marvin L WhiteEBS
- John D Fowler JrEBS
- Ronald RichardEBS
Questions about Keith Katkin
- What is Keith Katkin's role at Emergent BioSolutions Inc.?
- Keith Katkin reports to the SEC as director at Emergent BioSolutions Inc. (EBS), according to the latest filing on May 4, 2026. Keith Katkin has also filed as director at Syndax Pharmaceuticals Inc (SNDX) and director at Eledon Pharmaceuticals, Inc. (ELDN).
- How many shares does Keith Katkin own?
- After the latest filing that states it, Keith Katkin directly owned 96,294 shares of Emergent BioSolutions Inc. (EBS), 124,000 shares of Syndax Pharmaceuticals Inc (SNDX) and 8,575 shares of Eledon Pharmaceuticals, Inc. (ELDN). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Keith Katkin bought or sold stock recently?
- The most recent open-market purchase was on May 19, 2025: bought 10,000 shares of Syndax Pharmaceuticals Inc (SNDX) for $91.1K at an average of $9.11. The most recent open-market sale was on April 30, 2026: sold 15,481 shares of Emergent BioSolutions Inc. (EBS) for $128K at an average of $8.28.
- How do I get alerts when Keith Katkin files?
- Follow Keith Katkin on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Keith Katkin (SEC CIK 0001314596). Totals count each trade once, skipping amendments whose original is on file, from Feb 5, 2021 on. View on SEC EDGAR · Get this as JSON